DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $331,201 | -14.0% | 1,380 | -9.7% | 0.02% | -20.0% |
| Q1 2023 | $385,270 | +70.1% | 1,529 | +79.2% | 0.02% | +47.1% |
| Q4 2022 | $226,531 | -10.8% | 853 | +10.3% | 0.02% | -10.5% |
| Q4 2021 | $254,000 | +25.7% | 773 | -33.4% | 0.02% | +18.8% |
| Q2 2020 | $202,000 | -6.9% | 1,160 | -25.6% | 0.02% | -38.5% |
| Q1 2020 | $217,000 | -30.7% | 1,560 | -22.9% | 0.03% | +116.7% |
| Q4 2019 | $313,000 | +19.5% | 2,023 | -16.2% | 0.01% | -57.1% |
| Q3 2018 | $262,000 | -66.8% | 2,414 | -69.8% | 0.03% | -50.9% |
| Q2 2018 | $789,000 | -7.0% | 7,996 | -7.7% | 0.06% | -13.6% |
| Q1 2018 | $848,000 | +10.3% | 8,663 | +4.5% | 0.07% | +10.0% |
| Q4 2017 | $769,000 | +2.4% | 8,286 | -5.4% | 0.06% | -10.4% |
| Q3 2017 | $751,000 | +47.0% | 8,756 | +47.1% | 0.07% | -15.2% |
| Q2 2017 | $511,000 | -41.5% | 5,953 | -41.7% | 0.08% | -11.2% |
| Q1 2017 | $874,000 | +13.7% | 10,206 | +3.3% | 0.09% | -9.2% |
| Q4 2016 | $769,000 | – | 9,884 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |